Saturday 17 October 2026
Export MD’s income statement to Excel — free account
Pediatrix Medical Group, Inc.
MD Healthcare Medical Care Facilities
Pediatrix Medical Group, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.9 billion, down 4.92% from fiscal 2024. In the quarter to June 2026, revenue grew 4.04%, EPS grew 6.52%, free cash flow fell 6.56% and total debt fell 3.84%, each against the same quarter a year earlier.
27.38
0.38
−1.37%
Follow MD
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
8.82 | 11.03 | 10.38 | 12.12 |
P/S ratio |
0.74 | 0.94 | 0.90 | 1.03 | |
P/FCF ratio |
5.18 | 7.12 | 7.29 | 8.80 | |
P/Operating CF |
10.32 | 15.76 | (13.32) | 16.06 | |
P/B ratio |
1.59 | 2.08 | 1.97 | 2.28 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
0.81 | 0.99 | 1.03 | 1.12 | |
EV/EBITDA |
6.97 | 8.19 | 8.24 | 9.17 | |
EV/Operating CF |
5.37 | 6.99 | 7.70 | 8.88 | |
EV/FCF |
5.69 | 7.51 | 8.39 | 9.59 | |
Quick Ratio |
1.78 | 1.62 | 1.28 | 1.28 | |
Current Ratio |
1.83 | 1.66 | 1.33 | 1.32 | |
Net Debt/EBITDA |
1.89 | 1.79 | 5.47 | 2.87 | |
Debt/Assets |
27.39% | 26.59% | 28.54% | 27.42% | |
Debt/Equity |
0.68 | 0.69 | 0.67 | 0.66 | |
Asset Turnover |
0.90 | 0.87 | 0.95 | 0.92 | |
Operating CF/Net income |
1.91 | 3.39 | (4.39) | 3.15 | |
Capex/Depreciation |
(0.92) | (0.90) | (1.00) | (0.24) | |
Interest Coverage |
7.61 | 5.58 | 5.04 | 6.97 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
12.33% | 13.30% | 12.66% | 12.57% | |
Intangible Assets out of Total Assets |
0.58 | 0.57 | 0.62 | 0.60 | |
Share Based Compensation of Revenue |
1.04% | 1.08% | 0.98% | 1.04% | |
Graham Net Nets |
(0.42) | (0.34) | (0.35) | (0.29) | |
Graham Number |
21.21 | 21.20 | 22.44 | 22.84 | |
Earnings Yield |
11.34% | 9.07% | 9.63% | 8.25% | |
Free Cash Flow Yield |
19.29% | 14.05% | 13.72% | 11.36% | |
Revenue per Share |
5.83 | 5.87 | 5.89 | 6.14 | |
Operating CF per Share |
1.62 | 1.36 | (1.61) | 1.58 | |
Capex per Share |
(0.06) | (0.06) | (0.08) | (0.02) | |
Free Cash Flow per Share |
1.56 | 1.29 | (1.68) | 1.56 | |
Cash per Share |
5.47 | 5.94 | 4.07 | 5.09 | |
Shareholders Equity per Share |
10.53 | 10.30 | 10.86 | 11.09 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
10.53 | 10.30 | 10.86 | 11.09 | |
Free Cash Flow |
131.95 | 108.82 | (136.09) | 123.94 | |
Working Capital |
324.65 | 304.60 | 144.40 | 158.56 | |
Capital Expenditures |
(5.34) | (5.29) | (6.25) | (1.38) | |
Net Current Asset Value |
(591.54) | (617.33) | (604.68) | (589.22) | |
EV/EBIT |
7.81 | 9.08 | 9.12 | 10.18 | |
Capex to Sales |
0.01 | 0.01 | 0.01 | 0.00 | |
Price to Operating Income |
7.11 | 8.61 | 7.92 | 9.34 | |
| Other line items | |||||
Average Receivables |
261.52 | 257.46 | 244.90 | 242.81 | |
Average Payables |
342.86 | 409.11 | 235.55 | 302.60 | |
Average Assets |
2,138.14 | 2,199.70 | 2,031.89 | 2,116.22 | |
Average Common Equity |
811.58 | 815.40 | 833.88 | 857.37 |
Columns are period end dates